{"id":153794,"date":"2025-06-03T03:37:20","date_gmt":"2025-06-03T03:37:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/153794\/"},"modified":"2025-06-03T03:37:20","modified_gmt":"2025-06-03T03:37:20","slug":"biontech-stock-jumps-on-bristol-myers-squibb-cancer-drug-collaboration","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/153794\/","title":{"rendered":"BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration"},"content":{"rendered":"<p>       <img fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Sean Gallup \/ Getty Images Bristol Myers Squibb will pay $1.5 billion to BioNTech up front, with up to $9.6 billion in future payments possible based on certain milestones.\" loading=\"eager\" height=\"640\" width=\"960\" class=\"yf-1vr77wf loader\"\/> <\/p>\n<p>Sean Gallup \/ Getty Images<\/p>\n<p> Bristol Myers Squibb will pay $1.5 billion to BioNTech up front, with up to $9.6 billion in future payments possible based on certain milestones.            <\/p>\n<ul class=\"yf-1woyvo2\">\n<li class=\"yf-1woyvo2\">\n<p class=\"yf-1090901\">BioNTech&#8217;s U.S.-listed shares surged more than 15% Monday morning after the company said it will partner with Bristol Myers Squibb.<\/p>\n<\/li>\n<li class=\"yf-1woyvo2\">\n<p class=\"yf-1090901\">The companies will co-develop a drug currently in trials to treat several types of cancerous tumors.<\/p>\n<\/li>\n<li class=\"yf-1woyvo2\">\n<p class=\"yf-1090901\">Bristol Myers Squibb will pay $1.5 billion to BioNTech up front, $2 billion in &#8220;non-contingent anniversary payments through 2028,&#8221; and up to $7.6 billion in future payments possible based on certain milestones.<\/p>\n<\/li>\n<\/ul>\n<p class=\"yf-1090901\">U.S.-listed shares of BioNTech (BNTX) jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb (BMY).<\/p>\n<p class=\"yf-1090901\">The companies will work together to develop and eventually sell BNT327, one of BioNTech&#8217;s developmental antibodies that is in trials to treat a number of types of tumors. More than 20 trials are ongoing or planned to study the drug&#8217;s effectiveness in treating certain lung, breast, and other types of cancer.<\/p>\n<p class=\"yf-1090901\">Princeton, N.J.-based Bristol Myers Squibb &#8220;will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028.&#8221; BioNTech is also eligible to receive up to $7.6 billion in future payments based on certain developmental and regulatory milestones, while the companies will share manufacturing costs and profits or losses.<\/p>\n<p class=\"yf-1090901\">&#8220;Our collaboration with BMS, a pioneering leader in immuno-oncology, aims to accelerate and broadly expand BNT327\u2019s development to fully realize its potential,&#8221; BioNTech CEO Dr. Ugur Sahin said. &#8220;Our focus remains on advancing high-impact, pan-tumor programs and combination strategies in oncology, with BNT327 complementing our antibody-drug conjugate programs and mRNA-based immunotherapies.&#8221;<\/p>\n<p class=\"yf-1090901\">U.S.-listed shares of BioNTech were up 17% in the opening hour of trading, while Bristol Myers Squibb stock was down less than 1%.<\/p>\n<p class=\"yf-1090901\">Read the original article on <a href=\"https:\/\/www.investopedia.com\/biontech-stock-jumps-on-bristol-myers-squibb-cancer-drug-collaboration-11746217\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Investopedia;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Investopedia<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Sean Gallup \/ Getty Images Bristol Myers Squibb will pay $1.5 billion to BioNTech up front, with up&hellip;\n","protected":false},"author":2,"featured_media":153795,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8818],"tags":[65338,381,23890,748,65460,393,4884,16,15],"class_list":{"0":"post-153794","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-bristol","8":"tag-biontech","9":"tag-bristol","10":"tag-bristol-myers-squibb","11":"tag-britain","12":"tag-cancerous-tumors","13":"tag-england","14":"tag-great-britain","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114617348493285031","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/153794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=153794"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/153794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/153795"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=153794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=153794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=153794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}